Cardiovascular and Hematological Agents in Medicinal Chemistry最新文献

{"title":"Flavonoid-Enriched Extract from Desert Plant <i>Warionia saharae</i> Improves Glucose and Cholesterol Levels in Diabetic Rats.","authors":"Mohammed Ajebli, Mohamed Eddouks","doi":"10.2174/1871525717666190121143934","DOIUrl":"10.2174/1871525717666190121143934","url":null,"abstract":"<p><strong>Background and objective: </strong><i>Warionia saharae</i> Benth and Coss, is a medicinal plant used for its anti-diabetic properties in Morocco. This study was designed to examine the effect of the Flavonoid- Enriched Extract (FEE) obtained from <i>Warionia saharae</i> (W. saharae) on glucose and lipid metabolism in normal and streptozotocin (STZ)-induced diabetic rats.</p><p><strong>Methods: </strong>Acute (6 h) and sub-chronic (15 days) oral administration of FEE (10 mg/kg) was used to assess the glucose and lipid-lowering activity in normal and diabetic rats. Furthermore, glucose test tolerance, liver histopathological examination and <i>in vitro</i> antioxidant activity of FEE were carried out in this study.</p><p><strong>Results: </strong>Results indicated that FEE was able to exert antihyperglycemic activity. Additionally, FEE improved histopathological status of liver and pancreas in diabetic rats and possessed antioxidant activity.</p><p><strong>Conclusion: </strong>In conclusion, the present investigation revealed that FEE had potent antidiabetic effect in diabetic rats.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"17 1","pages":"28-39"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/f8/CHAMC-17-28.PMC6875866.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36883236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Underutilization of Cardiac Therapies in Patients with Acute Ischemic Stroke and Elevated Troponin.","authors":"Michael He, Subhasree Panchangam, Benjamín Cruz, D. Mukherjee","doi":"10.2174/1871525717666191019115338","DOIUrl":"https://doi.org/10.2174/1871525717666191019115338","url":null,"abstract":"INTRODUCTION Recent findings have shown that in acute ischemic stroke (AIS) patients, elevated troponin is associated with increased mortality. However, due to concerns of cerebral hypoperfusion and hemorrhagic transformation, current practice has been slow to apply proven cardiac therapies to these patients. This study aims to determine this rate of utilization. MATERIALS/METHODS A single-center review of 83 patients with AIS and measured troponin was conducted. Patients were stratified based on elevated and non-elevated troponin. Between groups, we measured the utilization of evidence-based cardiac therapies and used a univariate logistic regression to compare outcomes of mortality, re-hospitalization, recurrent acute ischemic stroke, recurrent acute myocardial infarction, and a composite of these outcomes. RESULTS Of 83 patients, 25 had elevated troponin and 58 had non-elevated troponin. There was no statistical difference in the use of cardiac therapies between the two groups. P2Y12 antagonists were infrequently used in both elevated and non- elevated troponin groups at 32% vs. 24% (p=0.64), as were ACE/ARBs at 56% vs. 69% (p=0.38). Those in the elevated troponin group encountered a statistically significant increase in composite endpoint 64% vs. 33% (OR 7.28, 95% CI 2.19-28.88, p<0.01). CONCLUSIONS Cardiac therapies are underutilized in patients with acute ischemic stroke and elevated troponin levels. In turn, this low usage may explain the increase in morbidity and mortality seen in these patients and the use of such therapies should be considered when treating this subset of patients as the cardioprotective nature of these therapies may outweigh the risks associated with them in AIS patients.","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1871525717666191019115338","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68038364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Utility of Troponin I and N Terminal-ProBNP among Patients with Heart Failure due to Non-Ischemic Cardiomyopathy and Important Correlations.","authors":"Tuoyo O Mene-Afejuku,&nbsp;Carissa Dumancas,&nbsp;Adedoyin Akinlonu,&nbsp;Olatunde Ola,&nbsp;Eder H Cativo,&nbsp;Shushan Veranyan,&nbsp;Persio D Lopez,&nbsp;Kwon S Kim,&nbsp;Gerald Pekler,&nbsp;Savi Mushiyev,&nbsp;Ferdinand Visco","doi":"10.2174/1871525717666190717160615","DOIUrl":"https://doi.org/10.2174/1871525717666190717160615","url":null,"abstract":"<p><strong>Background: </strong>Heart Failure (HF) is accompanied by a high cost of care and gloomy prognosis despite recent advances in its management. Therefore, efforts to minimize HF rehospitalizations is a major focus of several studies.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of 140 patients 18 years and above who had baseline clinical parameters, echocardiography, NT-ProBNP, troponin I and other laboratory parameters following a 3-year electronic medical record review. Patients with coronary artery disease, preserved ejection fraction, pulmonary embolism, cancer, and end-stage renal disease were excluded.</p><p><strong>Results: </strong>Of the 140 patients admitted with HF with reduced Ejection Fraction (HFrEF) secondary to non-ischemic cardiomyopathy, 15 were re-hospitalized within 30 days of discharge while 42 were rehospitalized within 6 months after discharge for decompensated HF. Receiver operating characteristic (ROC) cutoff points were obtained for NT-ProBNP at 5178 pg/ml and serum troponin I at 0.045 ng/ml. After Cox regression analysis, patients with HFrEF who had higher hemoglobin levels had reduced odds of re-hospitalization (p = 0.007) within 30 days after discharge. NT-ProBNP and troponin I were independent predictors of re-hospitalization at 6 months after discharge (p = 0.047 and p = 0.02), respectively, after Cox regression analysis.</p><p><strong>Conclusion: </strong>Troponin I and NT-ProBNP at admission are the best predictors of re-hospitalization 6 months after discharge among patients with HFrEF. Hemoglobin is the only predictor of 30 -day rehospitalization among HFrEF patients in this study. High-risk patients may require aggressive therapy to improve outcomes.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"17 2","pages":"94-103"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1871525717666190717160615","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37489572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluoroquinolones and the Risk of Aortic Aneurysm or Aortic Dissection: A Systematic Review and Meta-Analysis.","authors":"Prashanth Rawla,&nbsp;Marie Line El Helou,&nbsp;Anantha R Vellipuram","doi":"10.2174/1871525717666190402121958","DOIUrl":"https://doi.org/10.2174/1871525717666190402121958","url":null,"abstract":"<p><strong>Objectives: </strong>We performed a systematic review and meta-analysis to explore the risk of an aortic aneurysm or aortic dissection following fluoroquinolone administration.</p><p><strong>Methods: </strong>PubMed, Cochrane library, ClinicalTrials.gov, Embase and Google Scholar were systematically reviewed for controlled studies including adult patients exposed to fluoroquinolones with a primary outcome of aortic aneurysm or aortic dissection.</p><p><strong>Results: </strong>The meta-analysis was conducted by pooling the effect estimates of four controlled observational studies (one case-control, one case-crossover and two cohort studies). Fluoroquinolone administration more than doubled the risk to develop aortic aneurysm or aortic dissection within 60 days following fluoroquinolone exposure (adjusted Relative Risk [RR] (95% confidence interval [CI]) = 2.14 (1.93 - 2.36); I2 = 15.8%). The quality of the finding was rated as moderate. The risk increase for aortic aneurysm alone was found to be significant (adjusted RR (95% CI) = 2.23 (2.01 - 2.45); I2 = 0%) while the risk increase for aortic dissection alone was not found to be significant (adjusted RR = 1.88 (0.11 - 3.65); I2 = 74%). In subgroup analysis, the risk increase for aortic aneurysm or aortic dissection appeared to be higher in females compared to males (RR = 1.87 (1.24 - 2.51); I2 = 0% versus RR = 1.58 (1.25 - 1.92); I2 = 0%, respectively) and higher in older patients compared to younger patients (RR = 1.72 (1.37 - 2.07); I2 = 0% versus RR = 1.47 (0.91 - 2.04); I2 = 0%, respectively). Subgroup analysis of two studies which measured the duration-response analysis found that as the duration of fluoroquinolone therapy increased from 3 to 14 days to greater than 14 days, there was an increased risk of aortic aneurysm or dissection.</p><p><strong>Conclusion: </strong>The findings of this meta-analysis confirm the positive association between fluoroquinolones and the development of aortic aneurysm or dissection. The data tend to show that this association may be majorly driven by aortic aneurysm. Additionally, some risk factors appear to prevail including prolonged fluoroquinolone treatment and older age.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"17 1","pages":"3-10"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1871525717666190402121958","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37296063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and Adverse Consequences of Hookah/Waterpipe Use: A Systematic Review.","authors":"Rebecca Pratiti, D. Mukherjee","doi":"10.2174/1871525717666190904151856","DOIUrl":"https://doi.org/10.2174/1871525717666190904151856","url":null,"abstract":"Hookah smoking is becoming a popular trend globally. Waterpipe smoking is the second most prevalent form of alternate tobacco products. The rapid increase in the hookah use is being seen because of the misconception amongst public that hookah smoking is less harmful than cigarette smoking. Smoking ban policies had given impetus of switching from cigarette smoking to alternate tobacco products like waterpipe. Hookah users regard hookah to be more socially acceptable, less stigmatizing with flavors and to alleviate cigarette craving symptoms. Newer basic science research on animal models and human cells had shown consistently mutagenic, oxidative and inflammatory changes that could cause possible health effects of premalignant oral lesion and chronic diseases like atherosclerosis and chronic obstructive pulmonary disease. Studies on chemistry of waterpipe smoke had shown alarming results with the smoke containing seven carcinogens, 39 central nervous system depressants and 31 respiratory irritants. An enormous data exists showing waterpipe smoking causing various health effects. Hookah smoking effects on cardiovascular disease is additive with hookah containing a significant amount of nicotine, tar, and heavy metals causing both acute and chronic effects on the cardiovascular system. These effects include increased heart rate, blood pressure, prevalence of coronary heart disease, heart failure, ST elevation myocardial ischemia, recurrent ischemia and worse outcomes including mortality related to these diseases. The objectives of the review are to assess the factor associated with increasing use of hookah, its health effects, options for hookah smoking cessation and public health policy initiatives to mitigate waterpipe use.","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1871525717666190904151856","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68038307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Blood: A Futuristic Dimension of Modern Day Transfusion Sciences.","authors":"Rudrashish Haldar,&nbsp;Devendra Gupta,&nbsp;Shweta Chitranshi,&nbsp;Manish Kumar Singh,&nbsp;Sumit Sachan","doi":"10.2174/1871525717666190617120045","DOIUrl":"https://doi.org/10.2174/1871525717666190617120045","url":null,"abstract":"<p><p>Artificial blood is an innovative concept of transfusion medicine where specifically designed compounds perform the task of transport and delivery of oxygen in the body to replace this function of allogenic human blood transfusion. Several molecules have been developed in the past few decades to achieve this objective and continous refinements are being continuously made in the quest of the ideal blood substitute. Currently, available technology manufactures artificial blood from haemoglobin obtained from outdated human/bovine blood (Haemoglobin Based Oxygen Carriers) or utilizing Perfluorocarbons. These synthetic blood substitutes are advantageous in that they do not require compatibility testing, are free from blood borne infections, have prolonged shelf life and do not require refrigeration. Artificial blood is projected to have a significant impact on the development of medical care in the future. It can complement the current blood products for transfusion and create a stable supply of safe and effective products. It is likely to reduce the requirements of blood transfusions drastically especially in settings of trauma and surgery thereby reducing the reliance on banked donated blood.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"17 1","pages":"11-16"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1871525717666190617120045","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37336336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease.","authors":"Vishal Patel,&nbsp;Amit Joharapurkar,&nbsp;Samadhan Kshirsagar,&nbsp;Brijesh Sutariya,&nbsp;Maulik Patel,&nbsp;Hiren Patel,&nbsp;Dheerendra Pandey,&nbsp;Dipam Patel,&nbsp;Ramchandra Ranvir,&nbsp;Shekhar Kadam,&nbsp;Rajesh Bahekar,&nbsp;Mukul Jain","doi":"10.2174/1871525716666180118152158","DOIUrl":"https://doi.org/10.2174/1871525716666180118152158","url":null,"abstract":"<p><strong>Background: </strong>Obesity, diabetes and dyslipidemica are the key pathogenic stimulus that enhances progression of Non-Alcoholic Fatty Liver Disease (NAFLD). Coagonist of Glucagon Like- Peptide-1 (GLP-1) Receptor (GLP-1R) and Glucagon Receptor (GCGR) are being evaluated for obesity and diabetes. GLP-1 analogs have shown to reverse diabetes and obesity. Glucagon treatment reduces lipids after acute and chronic treatment.</p><p><strong>Objective: </strong>In this study, we have investigated the effect of co-agonist on the prevention of NAFLD induced by long-term feeding of High Fat Diet (HFD).</p><p><strong>Method: </strong>We have used HFD to induce NAFLD after chronic feeding in mice. Co-agonist treatment (150 µg.kg-1, s.c.) was initiated with induction of HFD, which was continued for 40 weeks. Body weight, food intake, glucose homeostasis, lipid profile, inflammatory and fibrotic markers were assessed at the end of treatment.</p><p><strong>Results: </strong>Co-agonist treatment prevented body weight gain, glucose intolerance and insulin resistance. Treatment with co-agonist reduced NEFA, increased FGF21 and adiponectin levels. Co-agonist increased glycerol release and energy expenditure, while decreased respiratory quotient. Co-agonist reduced lipids in circulation and liver. Expression of SREBP-1C, SCD-1, ACC and FAS were decreased, while ACOX1 and CPT1 were increased after co-agonist treatment. Inflammatory cytokine TNF-α and IL-6 in plasma and expression of MCP-1, TGF-ß, MMP-9, TNF-α, TIMP-1, α-SMA, and COL1A1 were decreased after co-agonist treatment. Plasma transaminases, hepatic TBARS, hepatic hydroxyproline and relative liver weight were suppressed after co-agonist treatment. Fat accumulation, inflammation and fibrosis were reduced in histological assessment of liver in co-agonist treated animals.</p><p><strong>Conclusion: </strong>Co-agonist prevented development of HFD-induced NAFLD by ameliorating obesity, diabetes, inflammation and fibrosis.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"16 1","pages":"35-43"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1871525716666180118152158","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35756106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perception of Patients Regarding Burdens and Benefits of Vitamin K Antagonists Among Patients with Nonvalvular Atrial Fibrillation.","authors":"Carlos Escobar,&nbsp;Vivencio Barrios,&nbsp;Luis Prieto,&nbsp;Jose María Lobos,&nbsp;Jose Polo,&nbsp;Diego Vargas","doi":"10.2174/1871525716666180608075834","DOIUrl":"https://doi.org/10.2174/1871525716666180608075834","url":null,"abstract":"<p><strong>Background: </strong>Achieving a good satisfaction with anticoagulant treatment should be a target in Atrial Fibrillation (AF) patients.</p><p><strong>Objective: </strong>To ascertain the perception of patients regarding burdens and benefits of anticoagulation with Vitamin K Antagonists (VKA).</p><p><strong>Methods: </strong>This was a multicenter cross-sectional/retrospective study conducted throughout Spain, in which AF patients taking VKA during the last year, attended at primary care setting were included. The Anti-Clot-Treatment Scale (ACTS) was used to determine perceived burdens and benefits with anticoagulation.</p><p><strong>Results: </strong>Overall, 1,386 patients (mean age 77.4 ± 8.7 years; 48.6% women; 64.2% permanent AF; CHA2DS2-VASc 3.9 ± 1.5; HAS-BLED 1.6 ± 0.9) were analyzed. The adequate anticoagulation control was achieved by 56.9/60.6% of patients according to direct method/Rosendaal method, respectively. Overall, mean ACTS Burdens scale score was 49.4 ± 8.8 and mean ACTS Benefits scale score 11.2 ± 2.2. Active patients, polymedication, elderly and visits to the nurse were associated with higher scores in the ACTS Burdens scale (lower perceived burden), whereas visits to the emergency department and primary care physician were associated with lower scores in the ACTS Burdens scale (higher perceived burden). Active patients, number of INR determinations, visits to the nurse, and an adequate INR control were associated with higher scores in the ACTS Benefits scale (higher perceived benefit), whereas visits to the emergency department and to the primary care physician were associated with lower scores in the ACTS Benefits scale (lower perceived benefit).</p><p><strong>Conclusion: </strong>Satisfaction with treatment was high among patients with AF chronically anticoagulated with VKA, suggesting that quality of life is not impaired in this population.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"16 2","pages":"106-113"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36203024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Flavonoid-rich Extract of Tamarix Articulata Vahl. on Glucose and Lipid Metabolism in Normal and Diabetic Rats.","authors":"Morad Hebi,&nbsp;Lhoussaine Hajji,&nbsp;Mohamed Eddouks","doi":"10.2174/1871525717666181211143858","DOIUrl":"https://doi.org/10.2174/1871525717666181211143858","url":null,"abstract":"<p><strong>Objective: </strong>The present study was carried out in order to evaluate the antidiabetic and antihyperlipidemic potential of Flavonoid-Rich Extract of Tamarix articulata (FRETA) in both normal and Streptozotocin (STZ)-induced diabetic rats.</p><p><strong>Material and methods: </strong>Normal and diabetic rats were treated with the FRETA for 7 days. At the end of treatment, a range of parameters was tested including blood lipid profile, histopathological changes in both liver and pancreas and Oral Glucose Tolerance Test (OGTT).</p><p><strong>Results: </strong>The blood glucose levels were lowered in both normal and diabetic rats treated with FRETA. Single oral administration of FRETA reduced blood glucose levels significantly in both normal and diabetic rats six hours after administration (P < 0.001; P < 0.0001 respectively). Furthermore, blood glucose levels were decreased significantly (P < 0.0001) in diabetic rats after 7 days of treatment. According to the oral glucose tolerance test, FRETA (5 mg/kg) was shown to prevent significantly the increase in blood glucose levels in diabetic treated rats. In addition, FRETA (5 mg/kg) showed a strong hypolipidemic effect both in normal and STZ rats after 7 days of once daily oral treatment. FRETA induced a significant decrease of plasma triglyceride and total cholesterol concentrations both in normal and diabetic rats. In contrast, plasma HDL-c levels were increased significantly (P < 0.0001) both in normal and diabetic rats. In addition, FRETA showed a remarkable in vitro antioxidant activity and revealed the inhibitory concentration of 50% of free radicals (IC50) of 31.92 µg/ml.</p><p><strong>Conclusion: </strong>In diabetic rats, flavonoids from Tamarix articulata showed antidiabetic and hypolipidemic activities.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"16 2","pages":"94-105"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36817129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective Effects of Diuretics Against the Development of Cardiovascular Disease in Patients with Chronic Kidney Disease: A Systematic Review.","authors":"Akinori Aomatsu,&nbsp;Susumu Ookawara,&nbsp;Kenichi Ishibashi,&nbsp;Yoshiyuki Morishita","doi":"10.2174/1871525716666180402145228","DOIUrl":"https://doi.org/10.2174/1871525716666180402145228","url":null,"abstract":"<p><p>Cardiovascular disease is one of the most important risk factors for mortality and morbidity in patients with Chronic Kidney Disease (CKD). This systematic review focuses on the protective effects of diuretics against the development of cardiovascular disease in patients with CKD. Among various kinds of diuretics, spironolactone, a mineralocorticoid receptor antagonist, has been shown to have protective effects against cardiovascular disease in patients with all stages of CKD, including predialysis, hemodialysis, and peritoneal dialysis. Low-dose loop diuretics have also been shown to have cardioprotective effects in patients with CKD during the pre-dialysis and hemodialysis stages; however, high-dose loop diuretics have failed to show these cardioprotective effects. The protective effects of other classes of diuretics, including thiazide and tolvaptan, against cardiovascular diseases in patients with CKD remain unclear.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"16 1","pages":"12-19"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1871525716666180402145228","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35968068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}